Inozyme (INZY) Enterprise Value to EBITDA Ratio

The linear price action on the EV/EBITDA chart for Inozyme Pharma, Inc. (INZY) is . The business relies on a closed system of clinical trials for genetic pathologies, where the company's survival is determined by FDA verdicts. Therapy safety is ensured by a strict temperature regime during drug transportation. Development prospects are based on the results of pyrophosphate level correction tests and obtaining orphan drug status.

Inozyme Pharma - INZY Company Value to EBITDA (period 07/04/2022 - 11/12/2026)

Comprehensive metric breakdowns and analytics for inozyme.com (INZY)

- current price and projected stock value:

Stock Price Inozyme Pharma|INZY - Analyst Median Target

- market capitalization details:

Market Valuation Inozyme Pharma, Inc.|INZY - Full Business Value

- business book valuation details:

Book Value per Share Inozyme Pharma|INZY - Total Stockholders' Equity|Market Capitalization to Book Value Ratio inozyme.com|INZY - Total Business Assets

- debt burden and liquidity indicators:

Total Debt to Equity Ratio Inozyme Pharma, Inc.|INZY - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Inozyme Pharma|INZY - Company Aggregate Indebtedness|Debts to Book Capitalization Inozyme Pharma, Inc.|INZY - Company Long-Term Loans and Borrowings|Company Short-Term Debts Inozyme Pharma|Quick Liquidity inozyme.com

- financial results and valuation multiples details:

INZY - Final Profit|Expected Profit Inozyme Pharma, Inc.|INZY - Price to Earnings Ratio|Forward P/E Multiple Inozyme Pharma|INZY - PEG Multiple|EV/EBITDA Multiple Inozyme Pharma, Inc.|INZY - Operating income before deduction of amortization|Earnings per share for the last twelve months Inozyme Pharma|INZY - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months inozyme.com|INZY - Earnings per share growth rate in current year|Expected earnings per share growth for next year Inozyme Pharma, Inc.

Fundamental valuation:Inozyme INZY

For the biotechnology sector, this indicator serves as a tool to compare the total enterprise value of a business with its operating profit before depreciation and taxes. By analyzing the EV/EBITDA ratio of a company across a financial timeline, an investor assesses asset value relative to the ability to generate cash flow. However, for Inozyme Pharma, Inc. (INZY), which focuses on R&D without commercial sales, this metric reflects a stage of pure capital expenditure.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics (APLT)|Enterprise Value to EBITDA Ratio Aileron Therapeutics RNTX|EV/EBITDA Multiple GELS (Gelteq)|EV/EBITDA Multiple Aytu BioPharma Inc AYTU|Chemomab - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio SRx Health Solutions Inc. SRXH|polyrizon-biotech.com (PLRZ) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation AEZS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclo Therapeutics|Company Value to EBITDA reneopharma.com RPHM|Enterprise Value to EBITDA Ratio CSCI (COSCIENS Biopharma)